The role of thromboelastometry and recombinant factor VIIa in trauma

Current Opinion in Anaesthesiology

Volumn 22, Issue 2, 2009, Pages 281-288

  Bartal, Carmi ^a   Yitzhak, Avraham ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Coagulopathy; Damage control strategy; Recombinant factor VIIa; Thromboelastometry; Trauma

Indexed keywords

FRESH FROZEN PLASMA; HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

ADJUVANT THERAPY; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; HEMODYNAMIC MONITORING; HEMORRHAGIC SHOCK; HOMEOSTASIS; HUMAN; INTERMETHOD COMPARISON; MORTALITY; NEUROSURGERY; PARAMETER; PATIENT SELECTION; PLASMA TRANSFUSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESUSCITATION; REVIEW; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; TREATMENT RESPONSE;

BRAIN INJURIES; CLINICAL PROTOCOLS; FACTOR VIIA; GUIDELINES AS TOPIC; HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGE, TRAUMATIC; PATIENT SELECTION; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; WOUNDS AND INJURIES;

EID: 68049094118     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e328325a6be     Document Type: Review

References (66)

1. Sauaia A, Moore FA. Epidemiology of trauma deaths: a reassessment. J Trauma 1995; 38:185-193.
2. Hoyt DB, Bulger EM, Knudson MM. Death in the operating room: an analysis of multicenter experience. J Trauma 1994; 37:426-432.
3. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354:1879.
4. Malone DL, Hess JR, Fingerhut A. Massive transfusion practice protocol. J Trauma 2006; 60:s91-s96.
5. Borgman M, Spinella PC, Perkins JG. Blood product replacement affects survival in patients receiving massive transfusion at a combat support hospital. J Trauma 2007; 63:805-813.
6. Brohi K. Acute traumatic coagulopathy. J Trauma 2003; 541:1127-1130.
7. Kaufman CR, Dwyer KM, Crews JD, et al. Usefulness of thromboelastography in assessment of trauma patient coagulation. J Trauma 1997; 42:716-722.
8. Schreiber MA, Perkins J, Kiraly L, et al. Early predictors of massive transfusion in combat causalities. Am Coll Surg 2007; 205:541-545.
9. MaCleod JBA. Early coagulopathy predicts mortality in trauma. J Trauma 2003; 55:39-44.
10. Watts DD, Trask A, Soeken F, et al. Hypothermic coagulopathy in trauma: effect of varying of hypothermia on enzyme speed, platelets function and fibrinolytic activity. J Trauma 1998; 44:846-854.
11. Deloughery TG. Coagulopathy in trauma patients: etiology, recognition and therapy. Crit Care Clin 2004; 20:13-24.
12. Hawryluk G, Cusimano M. The role of recombinant factor VII in neurosurgery: hope or hype? J Neurosurg 2006; 105:859-868.
13. Karadimov D, Binev K, Nachkov Y, Platikanov V. Use of activated recombinant factor VII during neurosurgery. J Neurosurg Anesthesiol 2003; 15:330-332.
14. Bartal C, Freedman J, Bowman K, Cusimano M. Coagulopathic patients with traumatic intracranial bleeding: defining the role of recombinant factor VIIa. J Trauma 2007; 63:725-732.
15. Schreiber MA. Damage control surgery. Crit Care Clin 2004; 20:101-111.
16. Meng ZH, Wolberg AS, Monroe DM, Hofman M. The effect of temperature and PH on activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55:886-891.
17. Goodnough LT. Treatment of critical bleeding in the future intensive care unit. Intensive Care Med 2002; 28:s221.
18. Yasuda CL,Morita ME, Nishimori FY, et al. Chronic subdural hematoma: study of 161 patients and the relationship with coagulation abnormalities. Arq Neurosiquitar 2003; 61:1011-1014.
19. Brohi K, Cohen MJ, Ganter MT, et al. Acute coagulopathy in trauma: hypoperfusion induces anticoagulation and hyperfibrinolysis. J Trauma 2008; 64:1211-1217.
20. Coats TJ, Heron M. The effect of hypertonic saline dextran on whole blood coagulation. Resuscitation 2004; 60:101-104.
21. Martinowitz U, Holcomb JB, Pusateri AE, et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001; 50:721-729.
22. Valeri CR, Cassidy G, Pivacek LE, et al. Anemia-induced increase in bleeding time: implications for treatment of nonsurgical blood loss. Transfusion 2001; 41:977-983.
23. Ho CH. The hemostatic effect of packed red cell transfusion in patient with anemia. Transfusion 1998; 38:1011-1014.
24. Spinella PC, Perkins JG, McLaughlin DF, et al. The effect of rFVIIa on mortality in combat-related causalities with severe trauma and massive transfusion. J Trauma 2008; 64:286-294.
25. Perkins JG, Schreiber MA, Wade CE, Holcomb JB. Early versus late rFVIIa in combat trauma patients requiring massive transfusion. J Trauma 2007; 62:1095-1101. A retrospective study showing clearly that early administration of rFVIIa in civilian and combat trauma patients who are anticipated to require massive resuscitation could reduce blood requirements.
26. Horton JD, Dezee KJ, Wagner M. Use of rFVIIa in trauma setting-practice patterns in United States trauma centers. Am Surg 2008; 74:413-417. Recent research providing a detailed picture about the different strategies of using factor VIIa in trauma by hospitals in the United States.
27. Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VIIa in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 3:640-648.
28. Beelkley AC. Damage control resuscitation: a sensible approach to the exsanguinating surgical patient. Crit Care Med 2008; 36:s267-s274. A current summary of the evidence supporting the damage control strategy in severe trauma patients.
29. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004; 57:709-718; discussion 718-719.
30. Ganter MT, Hofer CK. Point-of care coagulation monitoring: current status of viscoelastic techniques. Yearb Intensive Care Emerg Med 2007; 835-846. This article reviews the basic principles and properties of TEG and ROTEM and their clinical uses.
31. Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiologica 2007; 73:401-415. This article summarizes the pathophysiology of blood loss and impending coagulation disorders, the relative inferiority of routine coagulation tests and the various components of TEG/ROTEM.
32. Kozek-Langenecker S. Monitoring hemostasis in emergency medicine. Yearb Intensive Care Emerg Med 2007; 848-859. This article proposes, for the first time, a reasonable ROTEM-dependent algorithm for the treatment of trauma victims.
33. Rugeri L, Levrat A, David JS, et al. Diagnosis of early coagulation abnormalities in trauma patients by rotational thromboelastography. J Thromb Haemost 2007; 5:289-295. This is the first prospective observational study that assessed and proposed the use of ROTEM as a guiding tool for transfusion.
34. Levrat A, Gros A, Rugeri L. Evaluation of rotation thromboelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100:792-797. This study proved ROTEM to be a rapid and accurate tool for the early detection of hyperfibrinolysis in trauma patients.
35. Rizoli SB, Chughtai T. The emerging role of recombinant activated FVIIa in the treatment of blunt traumatic hemorrhage. Expert Opin Biol Ther 2006; 6:73-81.
36. Raobaikady R, Redman J, Ball JA, et al. Use of activated factor VIIa in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum, a double blind randomized placebo-controlled trial. Br J Anesth 2005; 94:586-591.
37. Rizoli SB, Nascimento B, Osman F, et al. Recombinant activated coagulation factor VII and bleeding trauma patients. J Trauma 2006; 61:1419-1425.
38. Spinella PC, Perkins JG, McLaughlin DF, et al. The effect of rFVIIa on mortality in combat-related causalities with severe trauma and massive transfusion. J Trauma 2008; 64:286-294. The first retrospective cohort study in combat trauma patients showing improved mortality rate by using rFVIIa in severe trauma patients.
39. Marik PE, Crowin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 2008; 36:2667-2674.
40. Viuff D, Lauritzizen B, Pusateri AH, et al. Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant fVIIa (Novoseven). Br J Anaesth 2008; 101:324-331.
41. Meng ZH, Wolberg AS, Monroe DM, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high dose factor in hypothermic and acidotic patients. J Trauma 2003; 55:886-891.
42. Kheirabadi BS, Delgado AV, Dubick MA, et al. In vitro effect of activated recombinant factor VIIa on coagulation properties of human blood at hypothermic temperatures. J Trauma 2007; 63:1079-1086.
43. Stein DM, Dutton RP, O'Connor J, et al. Determinants of futility of administration of recombinant factor VIIa. J Trauma 2005; 59:609-615.
44. Kheirabadi RS, Delgado AV, Dubick MA. In vitro effect of activated recombinant FVIIa on coagulation properties of human blood at hypothermic temperatures. J Trauma 2007; 63:1079-1086.
45. Siddique MS, Gregson BA, Fernades HM, et al. Comparative study of traumatic and spontaneous intracerebral hemorrhage. J Neurosurg 2002; 96:86-89.
46. Boffard KD, Riou B, Warren B. Recombinant factor VII as adjuvant therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double blind clinical trials. J Trauma 2005; 59:8-15.
47. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII intracerebral hemorrhage trial investigators: recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352:777-785.
48. Bugler E, Nathens A, Rivara F. Management of severe head injury: institutional variations in care and effect on outcome. Crit Care Med 2002; 30:1870-1876.
49. Lu J,Marmarou A, Choi S. Mortality from traumatic brain injury. Acta Neurochir 2005; 95:s281-s285.
50. Stein SC, Smith DH. Coagulopathy in traumatic brain injury. Neurocrit Care 2004; 1:479-488.
51. Zygun DA, Kortbeek JB, Fick GH, et al. Nonneurologic organ dysfunction in severe traumatic brain injury. Crit Care Med 2005; 33:654-660.
52. Mayer SA, Burn NC, Broderick J, et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005; 36:74-79.
53. Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke 2003; 34:224-229.
54. Mayer SA, Brun NC, Bergtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358:2127-2137. The phase III study showing contrast and less encouraging results than previous studies showed.
55. Park P, Fewel ME, Garton HJ. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 2003; 53:34-39.
56. Yusin Y, Perel A, Berkenstadt H, et al. The use of recombinant factor VIIa (Novoseven) for treatment of active or impending bleeding in brain injury: broadening the indications. J Clin Anesth 2006; 18:545-551.
57. Narayan RK, Mass AIR, Marshall LF, et al., rVIIa Traumatic ICH Study Group. Recombinant factor VIIa in traumatic intracerebral hemorrhage: results of a dose escalation clinical trial. Neurosurgery 2008; 62:776-788. The first prospective randomized control-dose escalation study of rFVIIa in traumatic ICH patients.
58. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin related coagulopathy in patients with acute subdural hematoma. Med Sci Monit 2002; 8:98-100.
59. Stein DM, Dutton RP, Kramer ME, et al. Recombinant factor VIIa: decreasing time to intervention in coagulopathic patients with severe traumatic brain injury. J Trauma 2008; 64:620-628. A well designed retrospective study using endpoint-directed therapy to support the controversial indication of rFVIIa in TBI.
60. Matheisen T, Benedikrsdonir K, Linquist M, Von Holst H. Intracranial traumatic and nontraumatic hemorrhagic complications of warfarin treatment. Acta Neurol Scand 1995; 91:208-214.
61. Brain Traumatic Foundation and AANS/CNS Joint section on neurotrauma and critical care. Guidelines for the management of severe traumatic brain injury. J Neurotrauma 2007; 24(Suppl):s1-s106.
62. Hansen MK, Jensen MK, Andersen C. Uncontrollable bleeding in a patient with head trauma treated with blood component therapy guided by thromboelastography. Ugeskr Laegr 2006; 168:3535-3536.
63. Nekludov M, Bellander B, Blomback M, Wallen HN. Platelet dysfunction in patients with severe TBI. J Neurotrauma 2007; 24:1699-1706.
64. James KMH, Melikian CN, Chowdary P, Mallett SV. Thromboelastographyguided rVIIa administration in a patient with refractory autoimmune idiopathic thrombocytopenia. Anesth Analg 2008; 107:402-405.
65. Young G, Yonekawa KE, Nekagawa PA, et al. rVIIa effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis 2007; 18:547-553.
66. Veldman A, Hoffman M, Ehrenforth S. New insights into the coagulation system and implication for new therapeutic options with recombinant factor VIIa. Curr Med Chem 2003; 10:797-811.